ベーチェット病治療薬の世界市場：予測（2022年～2028年）

当レポートでは、世界のベーチェット病治療薬市場について調査し、市場の概要とともに、薬剤タイプ別、投与経路別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

第3章 競合情勢

• Abbvie Inc
• Celgene Corp
• Cell medica Ltd
• Coherus biosciences Inc.
• Genor biopharma Co., Ltd
• 主要戦略分析
• COVID-19が主要参入企業に与える影響

第4章 市場セグメンテーション

• 世界のベーチェット病治療薬市場、薬剤タイプ別
  • コルチコステロイド
  • アダリムマブバイオシミラー
  • インフリキシマブのバイオシミラー
  • アプレミラスト
  • カナキヌマブ
• 世界のベーチェット病治療薬市場、投与経路別
  • 経口
  • 静脈内
  • 筋肉内
  • 局所

第5章 地域分析

• 北米
• 欧州
• アジア太平洋
• その他の地域

第6章 企業プロファイル

• Abbott Laboratories
• Biocon Ltd.
• F. Hoffmann-La Roche Ltd.
• Hospira Inc.
• Intas Pharmaceutical
• Novartis AG
• Panacea Biotec Ltd.
• R Pharm

LIST OF TABLES

• 1. GLOBAL BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
• 2. GLOBAL CORTICOSTEROIDS BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 3. GLOBAL ADALIMUMAB BIOSIMILAR BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 4. GLOBAL INFLIXIMAB BIOSIMILAR BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 5. GLOBAL APREMILAST BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 6. GLOBAL CANAKINUMAB BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 7. GLOBAL BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
• 8. GLOBAL ORAL BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 9. GLOBAL INTRAVENOUS BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 10. GLOBAL INTRAMUSCULAR BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 11. GLOBAL TOPICAL BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
• 12. GLOBAL BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
• 13. NORTH AMERICAN BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
• 14. NORTH AMERICAN BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG, 2021-2028 ($ MILLION)
• 15. NORTH AMERICAN BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
• 16. EUROPEAN BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
• 17. EUROPEAN BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG, 2021-2028 ($ MILLION)
• 18. EUROPEAN BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
• 19. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
• 20. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS DRUG, 2021-2028 ($ MILLION)
• 21. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
• 22. REST OF THE WORLD BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
• 23. REST OF THE WORLD BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG, 2021-2028 ($ MILLION)
• 24. REST OF THE WORLD BEHCET DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)

LIST OF FIGURES

• 1. IMPACT OF COVID-19 ON GLOBAL BEHCET DISEASE DRUG MARKET, 2021-2028 ($ MILLION)
• 2. IMPACT OF COVID-19 ON GLOBAL BEHCET DISEASE DRUG MARKET BY SEGMENT, 2021-2028 ($ MILLION)
• 3. RECOVERY OF GLOBAL BEHCET DISEASE DRUG MARKET, 2021-2027 (%)
• 4. GLOBAL BEHCET DISEASE DRUG MARKET SHARE BY DRUG, 2021 VS 2028 (%)
• 5. GLOBAL CORTICOSTEROID BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 6. GLOBAL ADALIMUMAB BIOSIMILAR BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 7. GLOBAL INFLIXIMAB BIOSIMILAR BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 8. GLOBAL APREMILAST BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 9. GLOBAL CANAKINUMAB BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 10. GLOBAL BEHCET DISEASE DRUG MARKET SHARE BY ROUTE OF ADMINISTRATION, 2021 VS 2028 (%)
• 11. GLOBAL ORAL BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 12. GLOBAL INTRAVENOUS BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 13. GLOBAL INTRAMUSCULAR BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 14. GLOBAL TOPICAL BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 15. GLOBAL BEHCET DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
• 16. US BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
• 17. CANADA BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
• 18. UK BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
• 19. FRANCE BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
• 20. GERMANY BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
• 21. ITALY BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
• 22. SPAIN BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
• 23. REST OF EUROPE BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
• 24. INDIA BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
• 25. CHINA BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
• 26. JAPAN BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
• 27. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
• 28. REST OF ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
• 29. REST OF THE WORLD BEHCET DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)

Global Behcet disease drug Market Size, Share & Trends Analysis Report by drug (Corticosteroid, Adalimumab Biosimilar, Infliximab Biosimilar, Apremilast, and Canakinumab) And By Route of Administration (Oral, Intravenous, Intramuscular and Topical), Forecast 2022-2028

The global Behcet disease drug market is anticipated to grow at a CAGR during the forecast period. The exact cause of Behcet disease is unknown to medical experts. They find two factors that may be the reason behind this disease. One is a genetic factor and the other is an environmental factor. Another partial cause of Behcet disease is somewhat a variation in the HLA-B gene. The main task of the HLA gene is to manufacture a type of protein in the body which is responsible for a consistent immune system. Scientists consider the HLB gene as part of the human leukocyte antigen complex. HLA complex plays a crucial task as it distinguishes protein made by my body from protein made by foreign bodies. These foreign bodies are viruses and bacteria. In a total number of people infected with Behcet disease, around one-third of them have been found variation in their HLA-B variation. For instance, in July 2020, Fujifilm Kyowa Kirin biologics has received approval to manufacture adalimumab biosimilar which is first in Japan. This will be used to treat entero-Behcet disease, arthritic psoriasis, and rheumatoid arthritis.

The global Behcet disease drug market is segmented based on drug, and route of administration. Based on drug, the market is segmented into Corticosteroid, Adalimumab Biosimilar, Infliximab Biosimilar, Apremilast And Canakinumab . Based on the route of administration, the market is sub-segmented into Oral, Intravenous, Intramuscular, and Topical. Among these, the Topical medication segment is anticipated to grow at a widespread rate during the forecast period. These medications are applied to ulcers and skin lesions so that pain and discomfort are relieved. Various creams are used on skin and genital lesions. For instance, a study done by scientists at National Eye Institute has discovered a unique population of B cells that puts down the immune system which reduces chronic inflammation. These cells reduced symptoms of eye disease such as autoimmune uveitis. Uveitis is a type of inflammatory eye disease that includes Behcet disease.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Asia Pacific are going to be a good market for Behcet disease drug. Being a populous region, the prevalence of Behcet disease is high in this region. This will be a driver for this market in the coming years. For instance, in March 2021, a study by Alvin F wells, who is a rheumatologist, explained a study that was done on patients with Behcet disease. Among 111 patients, most of them needed corticosteroids, and colchicine, adalimumab, and infliximab medications were used most number of the time. The study was published in the webinar titled 'Expert perspectives on the management of rheumatic diseases: Post ACR convergence 2020'.

The major companies serving the global Behcet disease drug market include AbbVie Inc., Celgene Corp., Cell Medica Ltd., Cohersu biosciences Inc., Geno biopharma Corp.Ltd. and others. For instance, in Sep 2021, Amgen wins a case on copyright infringement which was filed against Novartis Sandoz and Zydus Cadila. This case prevents these companies to use generic versions of apremilast.

Research Methodology

The market study of the global Behcet disease drug market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

• Financial reports of companies involved in the market.
• Whitepapers, research papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Behcet disease drug Market Research and Analysis by Drug Type.

2. Global Behcet disease drug Research and Analysis by Route Of Administration.

The Report Covers:

• Comprehensive Research Methodology of the global Behcet disease drug market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the global Behcet disease drug Market.
• Insights about market determinants that are stimulating the global Behcet disease drug market.
• Detailed and extensive market segments with the regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on The Global Behcet disease drug Market
• Recovery Scenario of Global Behcet disease drug Market
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. BY Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Abbvie Inc.
  • 3.1.1. Overview
  • 3.1.2. Financial Analysis
  • 3.1.3. SWOT Analysis
  • 3.1.4. Recent Developments
• 3.2. Celgene Corp.
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Cell medica Ltd.
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. Coherus biosciences Inc.
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Genor biopharma Co., Ltd.
  • 3.5.1. Overview
  • 3.5.2. Financial Analysis
  • 3.5.3. SWOT Analysis
  • 3.5.4. Recent Developments
• 3.6. Key Strategy Analysis
• 3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

• 4.1. Global Behcet disease drug Market by Drug TYPE
  • 4.1.1. Corticosteroids
  • 4.1.2. Adalimumab biosimilar
  • 4.1.3. Infliximab biosimilar
  • 4.1.4. Apremilast
  • 4.1.5. Canakinumab
• 4.2. Global Behcet disease drug Market by Route of Administration
  • 4.2.1. Oral
  • 4.2.2. Intravenous
  • 4.2.3. Intramuscular
  • 4.2.4. Topical

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. Abbott Laboratories
• 6.2. Biocon Ltd.
• 6.3. F. Hoffmann-La Roche Ltd.
• 6.4. Hospira Inc.
• 6.5. Intas Pharmaceutical
• 6.6. Novartis AG
• 6.7. Panacea Biotec Ltd.
• 6.8. R Pharm